Hypha’s newsletter for Q2 focusses on aspects of the metabolism of the experimental anti-cancer drug tivantinib. Tivantinib is extensively metabolised in humans including to various hydroxylated metabolites, of which two are major metabolites implicated under the FDA MIST guideline. Read more about how these human metabolites and other derivatives can be produced via microbial biocatalysis by clicking on the link below.
Hypha Q2 2017 newsletter tivantinib metabolism
